

# Study of Posoleucel (ALVR105, Formerly Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

**Status:** Recruiting

## Eligibility Criteria

**Age:** 1 year and over

This study is NOT accepting healthy

**Healthy Volunteers:** volunteers

Key

### Inclusion Criteria:

- $\geq 1$  year of age at the day of screening visit.
- No known or suspected clinically significant disease from AdV, BKV, CMV, EBV, HHV-6, and/or JCV
- Within 15 and 42 days of receiving a first allogeneic HCT and have demonstrated clinical engraftment
- Meet one or more of the following criteria at the time of randomization:
- Related (sibling) donor with at least one mismatch at one of these HLA-gene loci: HLA-A, -B or -DR
- Haploidentical donor
- Matched or Mismatched unrelated donor
- Use of umbilical cord blood as stem cell source
- Ex vivo graft manipulation resulting in T cell depletion
- Received anti-thymocyte globulin or alemtuzumab (Campath-1H) Key

### Exclusion Criteria:

- History of AdV, BKV, CMV, EBV, HHV-6, and/or JCV end-organ disease within 6 months prior to randomization
- Evidence of active Grade  $>2$  acute GVHD
- Presence of non-minor uncontrolled or progressive bacterial, viral or fungal infections
- Known history or current (suspected) diagnosis of CRS requiring treatment associated with the administration of peptides, proteins, and/or antibodies
- Ongoing therapy with high-dose systemic corticosteroids (ie, prednisone equivalent dose  $>0.5$  mg/kg/day) within 24 hours prior to dosing
- Relapse of primary malignancy other than minimal residual disease Note: Other protocol defined Inclusion/Exclusion criteria may apply.

## Conditions & Interventions

### Interventions:

Biological: Posoleucel (ALVR105), Biological: Placebo

### Conditions:

Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection

### Keywords:

Allogeneic Hematopoietic Cell Transplant, ALVR105, Posoleucel, Viralym-M

## More Information

**Contact(s):** Dee Rodriguez - ClinicalTrials@allovir.com

**Principal Investigator:**

**Phase:** Phase 2/Phase 3

**IRB**

**Number:**

**System ID:** NCT05305040

Thank you for choosing StudyFinder. Please visit <http://studyfinder.cctr.vcu.edu> to find a Study which is right for you and contact [ctrrecruit@vcu.edu](mailto:ctrrecruit@vcu.edu) if you have questions or need assistance.